TALQUETAMAB-TGVS: 828 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
828
Total FAERS Reports
63 (7.6%)
Deaths Reported
141
Hospitalizations
828
As Primary/Secondary Suspect
23
Life-Threatening
4
Disabilities
Prescription
Status
FDA Application: 761342 ·
First Report: 20211001 · Latest Report: 20250916
What Are the Most Common TALQUETAMAB-TGVS Side Effects?
#1 Most Reported
Cytokine release syndrome
162 reports (19.6%)
#2 Most Reported
Ageusia
88 reports (10.6%)
#3 Most Reported
Weight decreased
74 reports (8.9%)
All TALQUETAMAB-TGVS Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Cytokine release syndrome | 162 | 19.6% | 19 | 36 |
| Ageusia | 88 | 10.6% | 0 | 15 |
| Weight decreased | 74 | 8.9% | 3 | 12 |
| Dysgeusia | 73 | 8.8% | 5 | 7 |
| Skin exfoliation | 65 | 7.9% | 2 | 12 |
| Immune effector cell-associated neurotoxicity syndrome | 55 | 6.6% | 10 | 21 |
| Dry mouth | 53 | 6.4% | 1 | 9 |
| Off label use | 51 | 6.2% | 2 | 10 |
| Rash | 48 | 5.8% | 3 | 6 |
| Onychomadesis | 46 | 5.6% | 0 | 4 |
| Nail disorder | 45 | 5.4% | 2 | 3 |
| Taste disorder | 40 | 4.8% | 2 | 7 |
| Pyrexia | 39 | 4.7% | 0 | 11 |
| Death | 34 | 4.1% | 34 | 6 |
| Dry skin | 33 | 4.0% | 2 | 9 |
| Fatigue | 33 | 4.0% | 1 | 9 |
| Decreased appetite | 30 | 3.6% | 2 | 8 |
| Dysphagia | 29 | 3.5% | 2 | 6 |
| Plasma cell myeloma | 29 | 3.5% | 8 | 8 |
| Infection | 23 | 2.8% | 6 | 7 |
Who Reports TALQUETAMAB-TGVS Side Effects? Age & Gender Data
Gender: 44.5% female, 55.5% male. Average age: 65.0 years. Most reports from: US. View detailed demographics →
Is TALQUETAMAB-TGVS Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2021 | 1 | 0 | 0 |
| 2022 | 3 | 0 | 0 |
| 2023 | 42 | 3 | 15 |
| 2024 | 93 | 7 | 34 |
| 2025 | 92 | 4 | 23 |
What Is TALQUETAMAB-TGVS Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 422 |
| Plasma cell myeloma | 326 |
| Plasma cell myeloma refractory | 64 |
| Plasma cell leukaemia | 5 |
TALQUETAMAB-TGVS vs Alternatives: Which Is Safer?
TALQUETAMAB-TGVS vs TAMIFLU
TALQUETAMAB-TGVS vs TAMOXIFEN
TALQUETAMAB-TGVS vs TAMSULOSIN
TALQUETAMAB-TGVS vs TAPENTADOL
TALQUETAMAB-TGVS vs TAPINAROF
TALQUETAMAB-TGVS vs TARCEVA
TALQUETAMAB-TGVS vs TARLATAMAB
TALQUETAMAB-TGVS vs TARLATAMAB-DLLE
TALQUETAMAB-TGVS vs TASIGNA
TALQUETAMAB-TGVS vs TASIMELTEON
Official FDA Label for TALQUETAMAB-TGVS
Official prescribing information from the FDA-approved drug label.